Indoleamides are active against drug-resistant mycobacterium tuberculosis

Nature Communications

Volumn 4, Issue , 2013, Pages

  Lun, Shichun ^a   Guo, Haidan ^a   Onajole, Oluseye K ^b   Pieroni, Marco ^b,e   Gunosewoyo, Hendra ^b   Chen, Gang ^b   Tipparaju, Suresh K ^b,f   Ammerman, Nicole C ^a,c   Kozikowski, Alan P ^b   Bishai, William R ^a,c,d  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c AFRICA HEALTH RESEARCH INSTITUTE   (South Africa)

^d HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^e UNIVERSITY OF PARMA   (Italy)

^f MERRIMACK PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,5 BIS(4 CHLOROPHENYL) 2 METHYL 3 (4 METHYL 1 PIPERAZINYLMETHYL)PYRROLE; AMIKACIN; CAPREOMYCIN; ETHAMBUTOL; INDOLE DERIVATIVE; INDOLEAMIDE; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; MOXIFLOXACIN; N (2 ADAMANTYL) N' GERANYLETHYLENEDIAMINE; RIFAMPICIN; S 288T; UNCLASSIFIED DRUG;

ANTIMICROBIAL ACTIVITY; BACTERIUM; DISEASE CONTROL; DRUG RESISTANCE; IDENTIFICATION METHOD; MUTATION; TUBERCULOSIS;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL GENE; BACTERIAL STRAIN; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG PENETRATION; DRUG RESISTANCE; DRUG RESISTANT TUBERCULOSIS; DRUG STRUCTURE; DRUG TARGETING; HYDROGEN BOND; IN VITRO STUDY; MAXIMUM PLASMA CONCENTRATION; MINIMUM BACTERICIDAL CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR WEIGHT; MOUSE; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHYSICAL CHEMISTRY; SINGLE NUCLEOTIDE POLYMORPHISM; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANIMALS; ANION TRANSPORT PROTEINS; ANTITUBERCULAR AGENTS; BACTERIAL PROTEINS; CERCOPITHECUS AETHIOPS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; INDOLES; MICE; MICE, INBRED BALB C; MOLECULAR TARGETED THERAPY; MUTATION; MYCOBACTERIUM TUBERCULOSIS; POLYMORPHISM, SINGLE NUCLEOTIDE; TUBERCULOSIS, MULTIDRUG-RESISTANT; VERO CELLS;

EID: 84890954080     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms3907     Document Type: Article

References (27)

1. World Health Organization. Global Tuberculosis Report 2012 (2012).
2. United States Food and Drug Administration. Sirturo (bedaquiline) NDA 204384 Accelerated Approval Letter. 28 December 2012. (2012).
3. Andries, K. et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 307, 223-227 (2005). (Pubitemid 40116230)
4. Ananthan, S. et al. High-throughput screening for inhibitors of Mycobacterium tuberculosis H37Rv. Tuberculosis (Edinb) 89, 334-353 (2009).
5. Lilienkampf, A., Pieroni, M., Franzblau, S. G., Bishai, W. R. & Kozikowski, A. P. Derivatives of 3-isoxazolecarboxylic acid esters: a potent and selective compound class against replicating and nonreplicating Mycobacterium tuberculosis. Curr. Top. Med. Chem. 12, 729-734 (2012).
6. Mao, J., Wang, Y., Wan, B., Kozikowski, A. P. & Franzblau, S. G. Design, synthesis, and pharmacological evaluation of mefloquine-based ligands as novel antituberculosis agents. Chem. Med. Chem. 2, 1624-1630 (2007).
7. Pieroni, M. et al. Pyrido[1,2-a]benzimidazole-based agents active against tuberculosis (TB), multidrug-resistant (MDR) TB and extensively drugresistant (XDR) TB. Chem. Med. Chem. 6, 334-342 (2011).
8. Collins, L. & Franzblau, S. G. Microplate alamar blue assay versus BACTEC 460 system for high-throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium. Antimicrob. Agents Chemother. 41, 1004-1009 (1997). (Pubitemid 27194176)
9. Onajole, O. K. et al. Preliminary structure-activity relationships and biological evaluation of novel antitubercular indolecarboxamide derivatives against drugsusceptible and drug-resistant Mycobacterium tuberculosis strains. J. Med. Chem. 56, 4093-4103 (2013).
10. Ioerger, T. R. et al. Genome analysis of multi-and extensively-drug- resistant tuberculosis from KwaZulu-Natal, South Africa. PLoS One 4, e7778 (2009).
11. Payne, D. J., Gwynn, M. N., Holmes, D. J. & Pompliano, D. L. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat. Rev. Drug Discov. 6, 29-40 (2007). (Pubitemid 46020284)
12. Grzegorzewicz, A. E. et al. Inhibition of mycolic acid transport across the Mycobacterium tuberculosis plasma membrane. Nat. Chem. Biol. 8, 334-341 (2012).
13. La Rosa, V. et al. MmpL3 is the cellular target of the antitubercular pyrrole derivative BM212. Antimicrob. Agents Chemother. 56, 324-331 (2012).
14. Poce, G. et al. Improved BM212 MmpL3 inhibitor analogue shows efficacy in acute murine model of tuberculosis infection. PLoS One 8, e56980 (2013).
15. Tahlan, K. et al. SQ109 targets MmpL3, a membrane transporter of trehalose monomycolate involved in mycolic acid donation to the cell wall core of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 56, 1797-1809 (2012).
16. Ballell, L. et al. Fueling open-source drug discovery: 177 small-molecule leads against tuberculosis. Chem. Med. Chem. 8, 313-321 (2013).
17. Domenech, P., Reed, M. B. & Barry, 3rd C. E. Contribution of the Mycobacterium tuberculosis MmpL protein family to virulence and drug resistance. Infect. Immun. 73, 3492-3501 (2005). (Pubitemid 40745893)
18. Piddock, L. J. Multidrug-resistance efflux pumps-not just for resistance. Nat. Rev. Microbiol. 4, 629-636 (2006). (Pubitemid 44317025)
19. Tullius, M. V. et al. Discovery and characterization of a unique mycobacterial heme acquisition system. Proc. Natl Acad. Sci. USA 108, 5051-5056 (2011).
20. Varela, C. et al. MmpL genes are associated with mycolic acid metabolism in mycobacteria and corynebacteria. Chem. Biol. 19, 498-506 (2012).
21. North, E. J. et al. Design, synthesis and anti-tuberculosis activity of 1-adamantyl-3-heteroaryl ureas with improved in vitro pharmacokinetic properties. Bioorg. Med. Chem. 21, 2587-2599 (2013).
22. Remuiñán, M. J. et al. Tetrahydropyrazolo[1,5-a]pyrimidine- 3-carboxamide and N-benzyl-60,70-dihydrospiro[piperidine-4,40-thieno[3,2-c] pyran] analogues with bactericidal efficacy against Mycobacterium tuberculosis targeting MmpL3. PLoS One 8, e60933 (2013).
23. Vilcheze, C. & Jacobs, Jr W. R. The mechanism of isoniazid killing: clarity through the scope of genetics. Annu. Rev. Microbiol. 61, 35-50 (2007). (Pubitemid 350058198)
24. Sacksteder, K. A., Protopopova, M., Barry, 3rd C. E., Andries, K. & Nacy, C. A. Discovery and development of SQ109: a new antitubercular drug with a novel mechanism of action. Future Microbiol. 7, 823-837 (2012).
25. Jia, L. et al. Pharmacodynamics and pharmacokinetics of SQ109, a new diamine-based antitubercular drug. Br. J. Pharmacol. 144, 80-87 (2005). (Pubitemid 40192564)
26. Cole, S. T. et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 393, 537-544 (1998). (Pubitemid 28319235)
27. Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25, 1754-1760 (2009).